Please select the option that best describes you:
Topics:
Lung Cancer • Radiation Oncology • Thoracic Malignancies • Medical Oncology • Non-small cell lung cancer • EGFR+ • Cardiology
How do you monitor for cardiac toxicity in patients taking osimertinib?
Do you routinely check EKG's or echocardiograms? Or do you decide to only if the patient is at risk for Qtc prolongation or other symptoms?
Answer from: Medical Oncologist at Academic Institution
There are multiple studies that have explored the issue of cardiotoxicity from osimertinib. A large single center retrospective observational cohort series from Taiwan (n = 401) compared a matched cohort of patients treated with osimertinib [n = 253) with those treated with other EGFR TKIs (n = 195)...
Sign in or Register to read more